Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines
- PMID: 22508402
- PMCID: PMC3402625
- DOI: 10.1002/ibd.22912
Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines
Abstract
Background: The goal of this study was to assess the natural history of low-grade dysplasia (LGD) and its risk of progression in ulcerative colitis (UC) patients by prospective endoscopic surveillance.
Methods: Forty-two UC patients with LGD were followed prospectively using a uniform approach to surveillance colonoscopy with an average of 43 biopsies per exam. The interval between colonoscopies ranged from 3-12 months. Progression was defined as development of high-grade dysplasia (HGD) or cancer at subsequent colonoscopy or at colectomy. Univariate and multivariate analysis were performed to identify risk factors associated with progression.
Results: Patients were followed for an average of 3.9 years (range 1-13). Over that period 19% (8/42) of patients progressed to advanced neoplasia (two cancer, six HGD) while 17% (7/42) had persistent LGD and 64% (27/42) had indefinite dysplasia or no dysplasia at the end of follow-up. Multivariate analysis demonstrated that the number of biopsies with LGD at baseline was associated with an increased risk of progression to advanced neoplasia (relative risk [RR] 5.8, 95% confidence interval [CI]: (1.29-26.04). Among the 15 patients who underwent colectomy, four were found to have higher-grade neoplasia on their colectomy specimen than their preoperative colonoscopy, and these patients were more likely to be nonadherent with recommendations for colectomy.
Conclusions: The majority (81%) of UC patients with LGD did not progress to higher grades of dysplasia during a 4-year follow-up. Patients with three or more biopsies demonstrating LGD at a single colonoscopy were at increased risk for progression to advanced neoplasia.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Similar articles
-
Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance.J Crohns Colitis. 2013 Dec;7(12):e684-91. doi: 10.1016/j.crohns.2013.06.006. Epub 2013 Jul 31. J Crohns Colitis. 2013. PMID: 23916526
-
Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis.J Crohns Colitis. 2013 Dec;7(12):968-73. doi: 10.1016/j.crohns.2013.02.002. Epub 2013 Feb 20. J Crohns Colitis. 2013. PMID: 23433613
-
Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis.J Crohns Colitis. 2013 Dec;7(12):974-81. doi: 10.1016/j.crohns.2013.02.009. Epub 2013 Mar 20. J Crohns Colitis. 2013. PMID: 23523416
-
Dysplasia in ulcerative colitis--clinical consequences?Langenbecks Arch Surg. 2004 Oct;389(5):354-60. doi: 10.1007/s00423-003-0455-6. Epub 2004 Mar 13. Langenbecks Arch Surg. 2004. PMID: 15605166 Review.
-
Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis.Aliment Pharmacol Ther. 2007 Mar 15;25(6):657-68. doi: 10.1111/j.1365-2036.2007.03241.x. Aliment Pharmacol Ther. 2007. PMID: 17311598 Review.
Cited by
-
Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease.Curr Gastroenterol Rep. 2014 Sep;16(9):407. doi: 10.1007/s11894-014-0407-z. Curr Gastroenterol Rep. 2014. PMID: 25113042 Review.
-
Gegen Qinlian Decoction Attenuates Colitis-Associated Colorectal Cancer via Suppressing TLR4 Signaling Pathway Based on Network Pharmacology and In Vivo/In Vitro Experimental Validation.Pharmaceuticals (Basel). 2024 Dec 25;18(1):12. doi: 10.3390/ph18010012. Pharmaceuticals (Basel). 2024. PMID: 39861077 Free PMC article.
-
CD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis.Oncotarget. 2015 Aug 21;6(24):20058-69. doi: 10.18632/oncotarget.2780. Oncotarget. 2015. PMID: 25595911 Free PMC article.
-
Colon Cancer: Inflammation-Associated Cancer.Surg Oncol Clin N Am. 2018 Apr;27(2):269-287. doi: 10.1016/j.soc.2017.11.003. Epub 2017 Dec 15. Surg Oncol Clin N Am. 2018. PMID: 29496089 Free PMC article. Review.
-
From Colitis to Cancer: An Evolutionary Trajectory That Merges Maths and Biology.Front Immunol. 2018 Oct 16;9:2368. doi: 10.3389/fimmu.2018.02368. eCollection 2018. Front Immunol. 2018. PMID: 30386335 Free PMC article. Review.
References
-
- Devroede GJ, Taylor WF, Sauer WG, Jackman RJ, Stickler GB. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med. 1971;285:17–21. - PubMed
-
- Lennard-Jones JE. Colitic cancer: supervision, surveillance, or surgery? Gastroenterology. 1995;109:1388–1391. - PubMed
-
- Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994;343:71–4. - PubMed
-
- Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia. Gastroenterology. 1992;103:431–438. - PubMed
-
- Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003;125:1311–19. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical